MedTrace Logo

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

NCT04811365 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 379

Last updated 2023-04-06

No results posted yet for this study

Summary

This is a multi-center screening study with the primary objective to determine the prevalence of KIT D816V mutation in peripheral blood in patients with evidence of systemic mast cell activation (MCA).

Conditions

  • Systemic Mast Cell Activation
  • KIT D816V Mutation

Interventions

OTHER

Screening

After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms

Sponsors & Collaborators

  • Blueprint Medicines Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Italy
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811365 on ClinicalTrials.gov